AbbVie Capex To Revenue from 2010 to 2025

ABBV Stock  USD 210.01  1.95  0.92%   
AbbVie Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue is likely to outpace its year average in 2025. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.0165
Current Value
0.022
Quarterly Volatility
0.00472296
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.8 B, Interest Expense of 2.9 B or Selling General Administrative of 8.3 B, as well as many indicators such as Price To Sales Ratio of 3.46, Dividend Yield of 0.0288 or PTB Ratio of 99.06. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of AbbVie Inc over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. AbbVie's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

AbbVie Capex To Revenue Regression Statistics

Arithmetic Mean0.02
Geometric Mean0.02
Coefficient Of Variation24.36
Mean Deviation0
Median0.02
Standard Deviation0
Sample Variance0.000022
Range0.0187
R-Value(0.55)
Mean Square Error0.000017
R-Squared0.30
Significance0.03
Slope(0.0005)
Total Sum of Squares0.0003

AbbVie Capex To Revenue History

2024 0.0165
2023 0.0143
2022 0.012
2021 0.014
2020 0.0174
2019 0.0166
2018 0.0195

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.02  0.02 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.